Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants With Von Willebrand Disease (Velora Pioneer)

NCT06754852 is registered in ClinicalTrials.gov with Hemab ApS as lead sponsor.

NCT NCT06754852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06754852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-002 in Participants With Von Willebrand Disease (Velora Pioneer)
Lead sponsor
Hemab ApS
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 6, 2025
Completion date
July 31, 2027
Enrollment
108 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

von willebrand disease (vwd), von willebrand disease (vwd), type 1, von willebrand disease (vwd), type 2, von willebrand disease (vwd), type 3